All Posts By

Motif

Funding Strategy Update

By Announcements
The Board of Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today updated investors with its funding strategy following agreement on 14th April 2015 by the U.S. Food and Drug Administration (FDA) with the proposed Phase 3 clinical development programme for the Company's lead product candidate, iclaprim.  The Company anticipates commencing Phase 3 trials in the second half of this year. To fund these trials Motif is continuing to explore available options, including strategic partnerships with other pharmaceutical companies, non-dilutive government funding from grants, and market funding should the valuation of the Company be supportive. The Company is therefore pleased to announce that it has been selected to present at BioEquity Europe 2015. ...
Read More

Motif Gains FDA Agreement to Enter Phase 3 Clinical Development with Iclaprim

By Press Releases
Iclaprim safety and efficacy to be studied in two serious and life-threatening infections. Motif Bio plc (LSE: MTFB), announced today that the U.S. Food and Drug Administration (FDA) has agreed to the proposed Phase 3 clinical development programme for the Company’s lead product candidate, iclaprim. The Phase 3 programme is designed to obtain marketing approval for an intravenous formulation of iclaprim in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP) caused by Gram positive pathogens, including resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae). The FDA confirmed that two ABSSSI trials or one ABSSSI trial plus one HABP trial meeting their pre-specified primary endpoints are...
Read More

First Day of Dealings: Clinical stage biopharmaceutical company developing new antibiotics admitted to AIM

By Press Releases
Motif Bio plc, a clinical stage biopharmaceutical company specialising in the development of antibiotics, is pleased to announce that admission and trading of its Ordinary Shares commences today on AIM with the ticker MTFB. KEY POINTS: The Company has a lead antibiotic candidate, iclaprim, in clinical development. The directors anticipate that iclaprim could be ready for commercialisation within approximately 36 months. The Company is seeking to confirm in meetings with the FDA and EMA in the first half of 2015, that the clinical development plan for iclaprim meets regulatory guidelines and that two Phase III trials can be conducted. A Type C meeting is scheduled with the FDA for 14 April 2015. Resistance to antibiotics is a major global public...
Read More

Motif Bio Acquires Late Stage Antibiotic and Announces Pre-IPO Financing

By Press Releases
Amphion Innovations, a developer of medical, life science, and technology businesses, is pleased to announce that Partner Company, Motif BioSciences Inc. ("Motif"), has entered into an agreement to merge with a private company that holds the intellectual property and world-wide rights to a clinical stage antibiotic designed to be effective against MRSA and multi-drug resistant bacteria (the "Acquisition"). Motif plans to start Phase III trials this year in two serious hospital-acquired infections. Completion of the Acquisition is conditional inter-alia upon Motif completing an IPO before 31 March 2015. Motif is a US-based drug discovery and development company focused on developing solutions for the antibiotic crisis. As of 31 December 2013, Amphion owned 32% of Motif. Amphion is also pleased to...
Read More